ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Vitrakvi for Solid Tumors with NTRK Gene Fusions
November 29, 2018The Food and Drug Administration (FDA) has granted accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology and Bayer) for adult and pediatric patients with ..... -
FDA approves first oral TRK inhibitor with Loxo Oncology's Vitrakvi
November 28, 2018The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), for the treatment of solid tumours -
FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
November 28, 2018The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).
Pharma Sources Insight January 2025
